PSY39 LINGUISTIC VALIDATION OF THE LUPUS QOL QUESTIONNAIRE INTO 13 LANGUAGES  by Handa, ML et al.
Abstracts A137
the health utility associated with NeuP remains unclear. Knowledge regarding this
association is needed, as it impacts economic evaluations of treatments for NeuP. 
OBJECTIVES: To undertake a systematic review and meta-analysis of published
health utility values of patients with NeuP. METHODS: A detailed search of biblio-
graphic medical databases (Medline, Embase, Cochrane Library) and specialist eco-
nomic databases (NHS Centre for Reviews and Dissemination Economic Evaluation 
Database and Health Economics Evaluation Database) was undertaken (to September
2008). Reference lists of retrieved reports were also searched. Studies reporting utility
single-index measures (preference based) in NeuP were included. Random effects
meta-analysis was used to pool utility estimate across studies. The association of utili-
ties and a number of pre-deﬁ ned factors (NeuP indication, patient age, sex, duration 
and severity of pain and method of utility scoring) was examined using meta-regres-
sion. RESULTS: Twenty three studies reporting utility values in patients with NeuP 
were included, of which 11 were randomised trials that also reported the treatment
change in utility. The weighted pooled mean utility score across the studies was 0.48 
(95% CI: 0.44 to 0.53). There was evidence of substantial statistical heterogeneity 
across studies (P  0.0001). Although we found little evidence of variation in utility 
across patient characteristics or NeuP indication, increasing pain severity was found 
to be strongly associated with a reduction in utility. CONCLUSIONS: This study 
conﬁ rms that NeuP patients experience low utilities and therefore poor quality of life. 
Pain severity appears to be a major driver of the negative health impact of NeuP and
therefore needs to be considered in future economic evaluations of interventions for 
this patient population.
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OBJECTIVES: It is known the obesity increases in general population of the Republic 
of Serbia; the average value of the BMI in adults was 26.0 and 26.7 (2000 vs. 2006).
Proposed study, conducted in 2007 had been focused on the dietary behavior and 
consumption of dietary supplement among the adults, as well as gender differences.
METHODS: An observational, prospective study was performed among adults (both, 
males and females) in form of short questionnaire. The questionnaire included 14 
topics covering the following concepts: personal data, usage and knowledge of dietary 
supplements and other way for weight loss. A total of 993 adults were included, 224 
(22.56%) who used dietary supplements and 769 (77.44%) who didn’t. The study
was conducted in public pharmacy setting of three cities of Serbia (Belgrade, Novi Sad
and Nis). RESULTS: The mean value of BMI for male was 26.25 and female 23.79,
difference was statistically signiﬁ cant. It is showed the BMI values were higher in all
age groups of males compared to those of females, except in 60 years of age and older. 
In both cohorts groups the obesity became clinically signiﬁ cant in population older 
than 40 years of age. Of 224 examinees, only 10% used dietary supplements every 
day and 12% used it sparingly. The main purpose of their usage is improvement of 
physical appearance (49%), disease prevention (41%) and existing disease (10%). 
Previously to dietary supplements use the examinees tried to lose weight through diet 
(35%), exercise (24%), lower food portions without any diet (23%), more water 
consumption (11%), and 7% did not take any action. CONCLUSIONS: We conclude
the outcomes of the proposed study have showed the somewhat awareness and 
behavior toward obesity in domain of disease prevention and gender difference (males 
have higher BMI values) exist in the general population of the Republic of Serbia.
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OBJECTIVES: Obesity is a worldwide pandemic with serious health implications 
including increased risk of cardiovascular disease and type 2 diabetes. Unfortunately,
attempts to develop antiobesity medications have had mixed results due to poor toler-
ability and adverse events. Furthermore, the absence of a well developed patient
reported outcome (PRO) measure assessing the impact of antiobesity medication on
functioning and well-being has limited our understanding of treatment impact. This 
study validated the Treatment Related Impact Measure (TRIM)-Weight, a disease-
speciﬁ c PRO measure for assessing these relevant impacts. METHODS: The 43-item
TRIM-Weight, developed and debriefed in a previous study according to the 2006 
draft FDA guidelines, was validated in this web-based survey in 4 countries (United 
States, UK, Australia, Canada) for measurement structure and psychometric properties
to assess factor structure, reliability, validity for the total score and for each domain. 
RESULTS: Two hundred eight respondents completed the survey. Twenty-one of the 
43 items were omitted due to redundancy with other items, ceiling effects, poor factor
loadings, or poor conceptual ﬁ t resulting in a 22 item measure. A ﬁ ve-factor structure 
was achieved with domains of Daily Life, Weight Management, Treatment Burden, 
Experience of Side Effects, and Psychological Health. Internal consistency coefﬁ cients 
of the total score and each subscale ranged between 0.71 and 0.94 and test-retest
reliability ranged from 0.75 to 0.86. All pre-speciﬁ ed hypotheses for convergent and
the majority for known-groups validity were met. The completion time was estimated 
to be 3.38 (SD 2.49) minutes. CONCLUSIONS: The development of the TRIM-
Weight was conducted according to well-deﬁ ned scientiﬁ c principles. The total score, 
as well as each domain subscale, are a brief, conceptually sound, rigorously developed 
PRO measure with strong evidence supporting the psychometric properties. Use of the
TRIM-Weight in both clinical and research settings can facilitate development of 
patient-centered treatments resulting in a greater adherence, tolerability, and treatment 
efﬁ cacy.
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OBJECTIVES: Patients with Systemic Lupus Erythematosus (SLE) have shown signiﬁ -
cantly improved survival rates, causing researchers and physicians alike to become
increasingly interested in patients’ health-related quality of life. A variety of question-
naires exist to assess this measure; however, the Lupus Quality of Life Questionnaire
(LupusQoL) is the only disease-speciﬁ c questionnaire. Since this questionnaire was
only recently developed and psychometrically validated, it has yet to be linguistically 
validated for use across diverse cultures and languages. The objective of this study
was to create and validate thirteen translations of the LupusQoL. METHODS: To 
evaluate the linguistic validity of harmonized translations of the LupusQoL, bilingual 
(target language and English) interviewers cognitively debriefed subjects to assess their 
ability to paraphrase and understand the instructions, questions and responses within 
each translation. A total of thirteen translations were debriefed as part of this research
[Chinese (Taiwan), Dutch (Belgium), English (US/Canada), French (Belgium/France,
Canada), Greek (Greece), Hungarian (Hungary), Italian (Italy), Portuguese (Brazil),
Spanish (Argentina/Chile, Mexico, US/Canada), Swedish (Sweden)]. The results of the 
debrieﬁ ngs were compared on the basis of comprehension and number of suggested 
changes. RESULTS: Seventy-three subjects were interviewed, between 5 and 7 subjects
for each of the 13 languages tested. Subjects ranged in age from 19–76 years, with a 
mean age of 44.2 years and were stratiﬁ ed by educational level, including participants 
both with and without a high school degree. The overall item comprehension rate for
the LupusQoL was 99.5%. Intra-item and intra-language comprehension rates were 
also established. All items had a comprehension rate of greater than 91.8%, while 
most had 100%; all countries had at least a 98.1% rate. CONCLUSIONS: The 
translations of the instrument in this study demonstrated a high level of overall lin-
guistic validity. This research will facilitate inter-country comparisons of Systemic
Lupus Erythematosus and the pooling of data in multi-country studies.
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OBJECTIVES: Congenital hemophilia (CH) results from a deﬁ ciency of factors VIII 
or IX, and is associated with bleeding. Treatment can be complicated by potential
development of alloantibodies (inhibitors), which can result in more difﬁ cult to control
bleeding episodes and decreased quality of life (QoL) for the patient and family. Prior 
studies have only assessed QoL at the start and end of a treatment interval. This study 
reports the preliminary feasibility of evaluating the yet unknown day-to-day QoL
variability in CH patients with inhibitors. METHODS: Patients with CH with inhibi-
tors or their caregivers were asked to participate in a 90-day diary study that captured
all bleed treatments, daily activities, QoL (modiﬁ ed EQ-5D health state classiﬁ er,
health and pain visual analog scales (VAS)), family anxiety/stress, and activity changes.
Patients/caregivers kept primary diaries on paper with optional internet-based data 
entry. Graphical and quantitative representations were used to assess feasibility and 
discriminative validity of daily QoL assessment and impact of bleeds on QoL.
RESULTS: Patients who fully completed the diary study (n  3) each experienced 4–5
bleeds during diary days (n  273 total days). QoL patterns were distinctly different 
across patients (VAS 1-way ANOVA, p  0.001). VAS (Health, Pain) appeared 
more sensitive to daily variability than EQ-5D dimensions. Health and pain VAS
and self-care, usual activities, pain/discomfort, anxiety/depression dimensions dis-
criminated between combined bleed and non-bleed days (p  0.05). Family anxiety/
stress and activity changes were more pronounced in the patients with variable base-
line QoL suggesting concern over impending bleeds. CONCLUSIONS: Preliminary 
evidence suggests the VAS a is discriminative tool for bleeds for some patients, but a
large study will help to further validate the measure at the group level. Daily QoL
assessments may be valuable in assessing treatment interventions in patients with CH 
with inhibitors. Continuation of the study to completion with the planned 35 patients 
is warranted.
